Pricing Log in Create free account
Friday 6 November 2026 Export EXEL’s income statement to Excel — free account

Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.

Revenue
+10.2%
EPS
+22.8%
Free cash flow
−4.83%

Quarter to September 2026, against a year earlier

69.55 0.84 +1.22%
Market cap
$16.8B
P/E
20.1×
Fwd P/E
20.2×
Dividend yield
—
F-score
7/9
Altman Z
12.68
Beneish M
−2.61
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Exelixis, Inc. 10-Q filed Oct 29, 2026

Fiscal Q3 2026 · Period ended Oct 2, 2026 · Filed · accepted 4:16 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 4, 2025: 17 added · 17 removed · 68 modified; 11 with only figures updated